Back to top

Image: Bigstock

PFE Inks $2.6B Licensing Deal With Chinese Biotech for CAR-T Therapies

Read MoreHide Full Article

Key Takeaways

  • Pfizer signs a $2.6 billion deal for three CAR-T programs targeting autoimmune diseases.
  • The deal includes $330 million upfront and up to $2.3 billion in milestone payments.
  • Pfizer gains ex-China rights to develop, manufacture and commercialize the three programs.

Pfizer (PFE - Free Report) announced that it has entered into an exclusive licensing deal with China-based Starna Therapeutics for the latter’s three investigational chimeric antigen receptor T-cell (CAR-T) programs targeting autoimmune diseases.

Under the agreement, Starna Therapeutics will receive an upfront payment of $330 million. In addition, PFE will pay up to $2.3 billion in potential milestone payments, along with royalties on net sales of any approved products under the deal.

What Pfizer Gets Out of the Deal

PFE will obtain exclusive rights outside Greater China to develop, manufacture and commercialize three preclinical in vivo CAR-T programs. The company will lead clinical development in these territories and plans to manufacture the finished drug products for initial clinical studies at its U.S. facilities

In addition, Pfizer will receive rights to use Starna's proprietary in vivo CAR-T technology in inflammation, immunology and oncology. It will also hold options to exclusively license compounds developed under a separate research collaboration.

The company will also have the option to expand its licensing territory to include Greater China.

PFE Stock Performance

Year to date, the company’s shares have gained nearly 13% compared with the industry’s 21% growth.

Zacks Investment Research
Image Source: Zacks Investment Research

PFE Explores Next-Generation CAR-T Therapies

Unlike conventional CAR-T therapies, which involve collecting T cells from patients, genetically modifying and multiplying them in a laboratory before reinfusing them into the body, in vivo CAR-T therapies aim to genetically modify T cells directly inside the patient's body. This approach eliminates the need for extracting and processing cells outside the body, potentially reducing manufacturing complexities, treatment timelines and costs.

Through the deal with Starna, Pfizer is looking to capitalize on this emerging technology to develop next-generation treatments for autoimmune diseases.

PFE's move follows similar efforts by other large-cap drugmakers to strengthen their presence in the in vivo CAR-T space through strategic deals. AbbVie (ABBV - Free Report) acquired Capstan Therapeutics in 2025, gaining access to its lead in vivo CAR-T candidate, CPTX2309, which is being evaluated in a phase I study for autoimmune diseases.

Similarly, Eli Lilly (LLY - Free Report) acquired Orna Therapeutics earlier this year, adding its in vivo CAR-T platform and lead candidate, ORN-252, targeting B-cell-driven autoimmune diseases.

Pfizer Inc. Price

Pfizer Inc. Price

 

 

 

 

 

 

 

Pfizer Inc. price | Pfizer Inc. Quote

PFE’s Zacks Ranks

Pfizer currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Published in